Revolutionary TB Test Delivers Results in Under 30 Minutes — No Phlegm Required

A 150-Year-Old Problem Finally Gets a Modern Solution

For more than a century and a half, diagnosing tuberculosis has relied on one of medicine's most unpleasant specimens: phlegm. Since Dr. Robert Koch first identified the rod-shaped bacterium responsible for TB back in the 1800s, the diagnostic process has remained stubbornly unchanged — slow, imprecise, and deeply inconvenient for patients and healthcare workers alike.

Now, that's beginning to change.

Tuberculosis remains the world's deadliest infectious disease, claiming more than one million lives every year. Against that devastating backdrop, a new diagnostic tool is offering real hope — one that is faster, cheaper, more portable, and significantly more accurate than the century-old standard.

Why the Old Test Has Always Been a Problem

The conventional TB diagnostic method depends on collecting a patient's phlegm sample, then examining it under a microscope for the characteristic bacteria. On paper, it sounds straightforward. In practice, it's anything but.

"It's a nasty substance," says Dr. Adithya Cattamanchi, a pulmonologist at UC Irvine. "No one likes it. You don't like to cough it up. Health workers don't like working with it. It's difficult to handle in the lab because it's so viscous."

Beyond the sheer unpleasantness, the method presents serious clinical limitations. Children, elderly patients, and those already weakened by illness often cannot produce sufficient phlegm for testing. Worse still, the test itself is unreliable — it misses genuine TB cases roughly half the time and occasionally delivers false positives, sending healthy patients into unnecessary treatment.

Delays caused by missed diagnoses are far more than an inconvenience. According to Alfred Andama, a microbiologist at Makerere University College of Health Sciences in Uganda, patients who go undiagnosed continue spreading the disease as they move between healthcare facilities seeking answers. "They keep transmitting the disease," he says, "which puts others at risk of infection."

Introducing the MiniDock MTB: A Game-Changing Diagnostic Tool

Last year, Chinese biotech company Pluslife unveiled a new tuberculosis test called the MiniDock MTB, and the medical world took notice. The device works by processing either a phlegm sample or — crucially — a simple tongue swab. The sample is heated, spun down, and then scanned by the machine for tuberculosis DNA. The entire process takes less than 30 minutes.

The test's portability makes it especially valuable in low-resource settings where traditional laboratory infrastructure is limited or nonexistent.

Cost and Accessibility

One of the most compelling aspects of the MiniDock MTB is its affordability. Dr. Cattamanchi notes that the device itself carries a price tag of around $300, while individual tests cost just $3 to $4 each. That's a significant advantage over conventional microscopy setups and opens the door for far wider deployment across under-resourced healthcare systems.

"It's more affordable, it's more accessible," says Cattamanchi. "To have this low-cost option is really going to help countries scale up."

What the Research Shows

A major clinical study published in the New England Journal of Medicine has now validated the test's performance under real-world conditions. Cattamanchi, Andama, and their colleagues enrolled nearly 1,400 patients presenting with TB symptoms across seven countries in Africa and Asia.

The findings were encouraging: the MiniDock MTB met the World Health Organization's accuracy benchmarks whether phlegm or a tongue swab was used as the sample source. The WHO had already formally recommended the test prior to the study's publication — a significant endorsement from the world's leading global health authority.

"What we hope it means is that many more people will have access to high-quality TB testing," says Cattamanchi. "That would help get people the care they urgently need while simultaneously reducing transmission."

How the Pandemic Accelerated This Breakthrough

The MiniDock MTB didn't emerge in a vacuum. Its development was propelled in part by the wave of innovation triggered by the COVID-19 pandemic, during which swab-based molecular testing technology advanced rapidly thanks to an unprecedented injection of research funding and industry focus.

Companies like Pluslife, which honed their technology during the pandemic, have since redirected those capabilities toward tuberculosis — with results that researchers are describing as transformative.

Important Limitations to Keep in Mind

Despite the excitement, experts are careful to temper expectations with honesty about the test's current boundaries.

Lucica Ditiu, Executive Director of the U.N.'s Stop TB Partnership, acknowledges the enthusiasm surrounding the new tool but flags two important caveats.

Early-Stage Detection

First, the test may struggle to detect TB in its earliest stages, when the bacterial load in the body is still relatively low. "For that type of work, we don't think this is the tool yet," says Ditiu, suggesting further refinement may be needed.

Drug-Resistant TB

Second, the MiniDock MTB cannot differentiate between standard tuberculosis and drug-resistant strains that fail to respond to conventional antibiotics. Like the traditional microscope test, identifying drug-resistant TB still requires a separate, additional diagnostic step to determine the correct course of treatment.

That said, catching and treating TB early inherently reduces the likelihood of drug resistance developing in the first place — meaning widespread adoption of the new test could have long-term benefits that extend well beyond individual patient outcomes.

A Future Without the Microscope?

For clinicians like Cattamanchi, who has spent years working in health centers across central and eastern Uganda and witnessed firsthand the frustrating, months-long odyssey that patients endure before receiving a proper diagnosis, the arrival of the MiniDock MTB feels like a turning point.

Patients in underserved regions often visit multiple pharmacies and clinics, receiving symptomatic treatments for coughs and fevers before eventually reaching a facility equipped for TB testing. By that point, the disease may have already progressed significantly — and the patient may have unknowingly infected others along the way.

"My hope honestly is that after more than 150 years, we finally get rid of using a microscope," says Cattamanchi. "And that everyone who has TB symptoms is getting a high-quality molecular test. I think we're closer to that today than we've ever been before."

For the millions of people living in TB-endemic regions around the world, that day cannot come soon enough.